-
1 Comment
Alliance Pharma plc is currently in a long term uptrend where the price is trading 16.7% above its 200 day moving average.
From a valuation standpoint, the stock is 99.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.9.
Finally, its free cash flow grew by 36.9% to $12M since the same quarter in the previous year.
Based on the above factors, Alliance Pharma plc gets an overall score of 3/5.
| Exchange | LSE |
|---|---|
| CurrencyCode | GBP |
| ISIN | GB0031030819 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | 349M |
|---|---|
| PE Ratio | None |
| Target Price | 66.464 |
| Beta | 0.63 |
| Dividend Yield | None |
Alliance Pharma plc, a holding company, acquires, markets, and distributes consumer healthcare products and prescription medicines in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. It provides its products under the Aloclair, Anbesol, Asthon & Parsons, Forceval, Hydromol, Kelo-Cote, MacuShield, Vamousse, Nizoral, and Amberen brand names. The company was incorporated in 1996 and is headquartered in Chippenham, the United Kingdom.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for APH.LSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
